Walker Karen Marie 4
4 · Kyverna Therapeutics, Inc. · Filed Dec 17, 2025
Insider Transaction Report
Form 4
Walker Karen Marie
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-15$4.83/sh+23,998$115,910→ 46,634 total - Sale
Common Stock
2025-12-15$12.20/sh−23,998$292,776→ 22,636 total - Exercise/Conversion
Stock option (right to buy)
2025-12-15−23,998→ 85,865 totalExercise: $4.83Exp: 2033-11-05→ Common Stock (23,998 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions.
- [F2]25% of the original number of shares subject to the option vested on January 1, 2025, and 1/48th of the original number of shares subject to the option vests in monthly installments thereafter, subject to the Reporting Person's continuous service.